Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study
Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Draeger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaarll JPM, Van Criekinge W, Schalken JA (2019)
Publication Type: Journal article
Publication year: 2019
Journal
Book Volume: 22
Pages Range: 101-109
Journal Issue: 1
DOI: 10.1038/s41391-018-0076-3
Abstract
Background Low specificity of prostate-specific antigen results in a considerable number of unnecessary prostate biopsies in current practice. SelectMDx (R) predicts significant prostate cancer upon biopsy and is used to reduce the number of unnecessary initial prostate biopsies. Furthermore, potential overtreatment of insignificant prostate cancer can be reduced. Besides the diagnostic accuracy of the test, also the context in a specific country determines the potential health benefit and cost-effectiveness. Therefore, the health benefit and cost-effectiveness of SelectMDx were assessed in France, Germany, Italy, and Spain.
Involved external institutions
MDxHealth Netherlands
Netherlands (NL)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
MedValue
Netherlands (NL)
Hospital Universitario Puerta de Hierro - Majadahonda
Spain (ES)
Hospices Civils de Lyon (CHU)
France (FR)
Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC)
Netherlands (NL)
Valencia Oncology Institute Foundation / Fundación Instituto Valenciano de Oncología / Fundació Institut Valencià d’Oncologia (IVO)
Spain (ES)
Universiteit Gent (UGent) / Ghent University
Belgium (BE)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Hospital Universitario Miguel Servet
Spain (ES)
Netherlands (NL)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
MedValue
Netherlands (NL)
Hospital Universitario Puerta de Hierro - Majadahonda
Spain (ES)
Hospices Civils de Lyon (CHU)
France (FR)
Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC)
Netherlands (NL)
Valencia Oncology Institute Foundation / Fundación Instituto Valenciano de Oncología / Fundació Institut Valencià d’Oncologia (IVO)
Spain (ES)
Universiteit Gent (UGent) / Ghent University
Belgium (BE)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Hospital Universitario Miguel Servet
Spain (ES)
How to cite
APA:
Govers, T.M., Hessels, D., Vlaeminck-Guillem, V., Schmitz-Draeger, B.J., Stief, C.G., Martinez-Ballesteros, C.,... Schalken, J.A. (2019). Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer and Prostatic Diseases, 22(1), 101-109. https://dx.doi.org/10.1038/s41391-018-0076-3
MLA:
Govers, Tim M., et al. "Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study." Prostate Cancer and Prostatic Diseases 22.1 (2019): 101-109.
BibTeX: Download